Recommendations of the Groupe Francophone des Myélodysplasies (GFM) - Diagnostic approach and management of myelodysplastic syndromes, chronic myelomonocytic leukemias, and VEXAS syndrome (PubMed, Bull Cancer) - Oct 16, 2026 - "For lower-risk MDS, management primarily targets anemia through erythropoiesis-stimulating agents, luspatercept, and imetelstat (available very soon). Higher-risk forms are treated with azacitidine, potentially combined with venetoclax. Allogeneic hematopoietic stem cell transplantation continues to be refined at all stages, from donor selection to post-transplant management. Finally, the management of VEXAS syndrome is specifically detailed, encompassing corticosteroids, anti-inflammatory biotherapies, and azacitidine."
Journal • Review • Bone Marrow Transplantation • Chronic Myelomonocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation
|
|
Alice Garnier; Aline Renneville; Arsène Mekinian; Audrey Bidet; Christophe Willekens; Emmanuel Gyan; Evelyne Chartier; Fatiha Chermat; Jacqueline Dubow; Jean-Baptiste Micol; Jose-Miguel Torregrosa-Diaz; Juliette Pénichoux; Lin-Pierre Zhao; Lionel Ades; Lise Larcher; Lucie Freiman; Maël Heiblig; Marie Robin; Marie Sebert; Marie-Anne Hospital; Mathieu Meunier; Maud D'Aveni-Piney; Michaela Fontenay; Nicolas Chapuis; Odile Rauzy; Olivier Kosmider; Orianne Wagner-Ballon; Pierre Fenaux; Pierre Peterlin; Raphael Itzykson; Sophie Dennetiere; Sophie Dimicoli-Salazar; Sophie Park; Thibault Comont; Thomas Cluzeau; Valérie Bardet
|